Article:Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity. (5327767)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q39175599. Its title is Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity. and the publication date was 2017-02-13. The initial author is Mostafa Wanees Ahmed El husseny.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Journal of Diabetes Research

Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity

  • Mostafa Wanees Ahmed El husseny
  • Mediana Mamdouh
  • Sara Shaban
  • Abdelrahman Ibrahim Abushouk
  • Marwa Mostafa Mohamed Zaki
  • Osama M. Ahmed
  • Mohamed M. Abdel-Daim

1Faculty of Medicine, Fayoum University, Fayoum, Egypt

2NovaMed Medical Research Association, Cairo, Egypt

3Fayoum Medical Student Association, Fayoum, Egypt

4Faculty of Medicine, Ain Shams University, Cairo, Egypt

5Faculty of Clinical Pharmacy, Fayoum University, Fayoum, Egypt

6Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt

7Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, 41522, Egypt

Publication date (ppub): /2017

Publication date (epub): 2/2017

Abstract

Adipokines are bioactive molecules that regulate several physiological functions such as energy balance, insulin sensitization, appetite regulation, inflammatory response, and vascular homeostasis. They include proinflammatory cytokines such as adipocyte fatty acid binding protein (A-FABP) and anti-inflammatory cytokines such as adiponectin, as well as vasodilator and vasoconstrictor molecules. In obesity and type II diabetes mellitus (DM), insulin resistance causes impairment of the endocrine function of the perivascular adipose tissue, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and an increased production of reactive oxygen species. Recent studies have shown that targeting plasma levels of adipokines or the expression of their receptors can increase insulin sensitivity, improve vascular function, and reduce the risk of cardiovascular morbidity and mortality. Several reviews have discussed the potential of adipokines as therapeutic targets for type II DM and obesity; however, this review is the first to focus on their therapeutic potential for vascular dysfunction in type II DM and obesity.

Paper

1. Introduction

According to the World Health Organization (WHO) reports, obesity affects 1.1 billion adult individuals worldwide, 300 millions of whom are clinically obese with a body mass index (BMI) of ≥ 30 kg/m2 [[1], [2]]. It can cause several health problems, including hypertension, stroke, and ischemic heart disease [[1]]. An analysis by the Prospective Studies Collaboration (PSC) of data from over 900,000 individuals showed that the median survival rate decreases by 8 to 10 years for obese subjects with a BMI of 40 to 45 kg/m2, compared to those with a normal BMI, primarily due to vascular complications [[3]].

Obesity and type II diabetes mellitus (DM) are linked because both are components of the so-called “metabolic syndrome (MS).” Metabolic syndrome is defined by the WHO as the presence of insulin resistance (IR) and any two of the following criteria which include (1) increased abdominal girth, (2) hypertension, (3) elevated triglycerides levels, (4) low high-density lipoprotein level, and (5) elevated blood glucose levels (type II DM) [[4]]. It is now considered a major health problem with a prevalence of 34% among the United States population, and it has a significant association with increased risks of morbidity and mortality from cardiovascular diseases [[5]].

Adipose tissue is no longer considered a passive site for storage of energy in the form of triacylglycerols [[6]], but it is also an important endocrine gland which secretes several bioactive molecules [[7][10]]. Adipokines (or adipocytokines) are bioactive molecules that regulate several physiological functions such as energy balance, insulin sensitization, appetite regulation, inflammatory response, and vascular homeostasis [[11], [12]]. They are primarily secreted by adipose tissue cells (adipocytes), but recent studies found that intestinal epithelium, adrenal gland, skeletal muscle, leukocytes, macrophages, hepatocytes, and cardiomyocytes can secrete them as well [[2], [13]].

All blood vessels are surrounded by a layer of perivascular adipose tissue (PVAT), in which adipocytes are encroaching into the adventitia of the vessel, permitting secreted factors from PVAT to enter the blood circulation instantly [[14][16]]. This tissue is involved in vascular inflammation, adjustment of vascular tone, and smooth muscle cells' proliferation [[17]]. It can promote endothelium-dependent vasodilatation by releasing nitric oxide (NO), adiponectin, and adipocyte derived relaxing factor (ADRF), which activate potassium channels of the vascular smooth muscle cells and thus inhibit the vasoconstrictive effect of multiple agonists including phenylephrine, serotonin, and angiotensin II [[14], [16]]. On the other hand, PVAT secretes adipocyte fatty acid binding protein (A-FABP) and adipose tissue-derived constricting factor (ADCF), which induce vasoconstriction and activate NADPH oxidase enzyme, increasing the release of reactive oxygen species (ROS) [[17]].

In obese and type II diabetics, insulin resistance causes impairment of the endocrine function of PVAT, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and increasing of the production of ROS, all of which lead to endothelial dysfunction and vascular hypertension [[2]]. A recent study has shown that adiponectin needs to be 10 times higher to mediate the same vasodilator effect in obese individuals, compared to normal controls [[18]].

Moreover, increased systemic and vascular oxidative stress in these patients directly inhibits the release of NO, which mediates vasodilatation and protects the arterial wall from atherogenic mediators, leading to endothelial dysfunction and a proatherogenic environment [[19]]. Several studies have shown that adipose tissue inflammation promotes the hepatic production of C-reactive protein (CRP) and fibrinogen, which stimulate the expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), creating a prothrombotic state, which gradually progresses to cardiovascular disease [[11], [12], [20], [21]].

Several reviews have discussed the potential of adipokines as therapeutic targets for type II DM and obesity [[22], [23]]; however, this review is the first to focus on their therapeutic potential for vascular dysfunction in type II DM and obesity. This article explores the vascular functions of different adipokines, how these functions are impaired in insulin resistance states, and how targeting adipokines can serve as a therapeutic strategy for these abnormalities.

2. Vascular Effects of Adipokines

2.1. Adiponectin

Adiponectin is an insulin-sensitizing adipokine, involved in glucose and lipid homeostasis, through activation of AMP-activated protein kinase (AMPK) [[24], [25]]. It works through its receptors, including AdipoR1 (skeletal muscle), AdipoR2 (liver), and T-cadherin (cardiovascular system) [[2]]. In the circulation, adiponectin is present as three distinct oligomeric complexes, and it was found that the distribution, not the absolute amount of total adiponectin, determines insulin sensitivity [[26], [27]]. In skeletal muscles, it decreases lipid accumulation by promoting fatty acid β-oxidation and increasing glucose uptake [[28], [29]]. In the liver, it inhibits both gluconeogenesis and lipogenesis, counteracting hyperglycemia and hepatic steatosis [[30], [31]]. Unlike most adipokines, adiponectin is inversely proportionate to the degree of obesity, meaning that its concentration decreases when obesity becomes more severe and is restored when the body weight is reduced [[32]].

In terms of vascular functions, adiponectin has several anti-inflammatory and endothelium-protective effects. It induces downregulation of the myelomonocytic precursor cells, inhibits the phagocytic activity of mature macrophages, and reduces the release of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-10 (IL-10), and IL-1 receptor antigen (IL-1RA) [[33]]. It inhibits leukocyte-endothelium reaction, which is a major risk factor for both macrovascular and microvascular complications [[34]].

In case of vascular endothelial damage or tissue ischemia, it promotes migration of endothelial progenitor cells (EPCs) towards the area of vascular damage, where they turn into mature endothelial cells. Therefore, in humans, plasma levels of adiponectin are directly proportionate with the number of circulating EPCs [[35]]. Furthermore, animal studies have shown impaired repair of vascular injury in adiponectin deficient mice with deficient recruitment of ECPs from the bone marrow to the site of injury [[36]].

On the cellular endothelial level, it reduces production of ROS, usually caused by elevated glucose and low-density lipoprotein (LDL) levels, through inhibition of the NAD(P)H oxidase enzyme [[37]]. Clinical studies in humans showed that increased plasma levels of adiponectin are associated with diminished markers of oxidative stress [[38]]. Animal studies have found that adiponectin suppresses the activation of nuclear factor-kappa B (NF-kB) in endothelial cells, through a protein kinase A (PKA) dependent pathway [[39]]. Other studies have indicated that adiponectin suppresses apoptosis and caspase-3 activity in human umbilical vein endothelial cells (HUVECs) through activation of the AMPK signaling pathway, and it prevents angiotensin II-induced apoptosis of bovine endothelial cells by restoring eNOS-HSP90 reaction [[24], [40]].

Moreover, adiponectin has an antiatherogenic role through inhibition of smooth muscle cells' proliferation and migration [[41]], which are induced by atherogenic growth factors, including heparin-binding epidermal growth factor, platelet-derived growth factor- (PDGF-) BB, and basic fibroblast growth factor [[38], [42]]. Kubota et al. reported excessive smooth muscle migration and proliferation with neointimal hyperplasia in mice deficient of adiponectin [[43]]. Moreover, it was shown that patients with angina pectoris with lower levels of adiponectin are at a high risk for progression of their atherosclerotic lesions with development of acute coronary syndrome [[44]]. Adiponectin guards against myocardial ischemia/reperfusion (I/R) injury by inhibiting the production of local TNF-α and cardiomyocyte apoptosis that are induced by I/R injury [[45]]. It also alleviates monocyte attachment to endothelial cells through suppression of resistin-induced expression of adhesion molecules [[40]].

Different mechanisms link obesity-associated hypertension to decreased levels of adiponectin including hyperactivity of the renin-angiotensin system and sympathetic nervous system, endothelial dysfunction, and natriuresis impairment [[46]]. A recent study estimated that each 1 mg/mL increase in adiponectin levels was associated with a 6% reduced risk of hypertension [[47]].

2.2. Adipocyte Fatty Acid Binding Protein (A-FABP)

Adipocyte fatty acid binding protein, also termed FABP-4, is a transport protein that delivers its endogenous ligands, including oleic acid, retinoic acid, and arachidonic acid to the nuclear receptor [peroxisome proliferator-activated receptor-γ (PPAR-γ)], thus encouraging the transcriptional activity of the receptor, which plays a major role in lipolysis [[48]]. It is mainly expressed in adipocytes, but it can be also produced from macrophages. Its level in human plasma ranges from 10 to 50 ng/mL, a level that is much higher than other adipokines [[49]]. Elevated plasma levels of A-FABP can serve as a marker for several obesity-related metabolic abnormalities, endothelial dysfunction, hypertension, atherosclerosis, and coronary heart disease [[48]]. It was found that A-FABP increases as coronary heart disease progresses from one vessel to three-vessel disease [[50]]. Its serum level is directly proportionate with adiposity measures (BMI, fat percentage, and waist circumference) and serum levels of lipocalin-2 and hsCRP, which are two inflammatory markers associated with atherosclerosis and coronary artery disease [[51]]. However, it is inversely correlated with the serum levels of adiponectin. Built upon these findings, A-FABP is a proinflammatory cytokine that links obesity to vascular dysfunction.

The expression of A-FABP in macrophages can be triggered by saturated free fatty acids, oxidized LDL, and Toll-like receptor activators. Such expression causes intracellular accumulation of cholesterol-ester and formation of foam cells, while inhibiting A-FABP expression increases cholesterol efflux and inhibits the activity of NF-kB and cyclooxygenase-II enzyme. Another proinflammatory mechanism of A-FABP is its positive feedback on C-Jun N-terminal kinase (JNK), a major mediator of insulin resistance and vascular dysfunction. This means that inflammatory stimuli activate JNK in macrophages, which enhance gene transcription of A-FABP. Conversely, elevated A-FABP levels increase JNK phosphorylation, leading to its activation and increased levels of proinflammatory cytokines [[52]].

2.3. Leptin

Leptin is another adipokine which regulates food intake by inducing satiety and facilitating energy expenditure. Its serum levels are directly proportionate with the body adipose mass and adipocyte size. Clinical studies showed a positive correlation between leptin levels and development of macrovascular complication of obesity such as myocardial infarction and cerebral stroke [[53], [54]]. A large prospective study on leptin and cardiovascular risk (West of Scotland Coronary Prevention Study) highlighted leptin as an independent predictor of coronary events such as cardiac death, myocardial infarction, and coronary revascularization with a great prognostic value in atherosclerotic patients [[55]]. Another application for these clinical observations is the use of leptin-adiponectin ratio as an indicator of subclinical atherosclerosis because it correlates with the magnitude of the intima-media thickness (IMT) of common carotid artery. A recent study showed increasing leptin expression with diminished adiponectin levels in patients with coronary artery disease [[56]].

The association of leptin to hypertension is an interesting point of controversy [[57]]. Under physiological conditions, leptin induces endothelial NO production with subsequent vasodilation [[58]]. However, in cases of obesity-associated hyperleptinemia, this vasodilatory effect is lost with subsequent development of hypertension. The controversy upon the peripheral effect of leptin supports the proposed theory of an involved central mechanism. Leptin, through its central receptors, has a stimulatory effect on the sympathetic nervous system with subsequent elevation of blood pressure in cases of hyperleptinemia [[59]]. Human leptin deficiency syndrome is associated with severe obesity and hypotension that can be explained by lack of its central effect on satiety centre and sympathetic nervous system [[60]].

The role of leptin as a prothrombotic factor in the pathogenesis of cardiovascular disease is now well established. Animal studies have shown that leptin can increase platelet aggregation with subsequent arterial thrombosis [[61], [62]]. Furthermore, leptin at high concentrations can induce expression of vascular adhesion molecules and the prothrombotic tissue factor [[63]]. Clinical studies have shown a positive correlation between plasma levels of leptin and plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator, von Willebrand factor (vWF), and fibrinogen [[63]]. Leptin also promotes the expression of other inflammatory adipocytokines including TNF-α, IL-2, IL-6, and monocyte chemotactic protein 1 (MCP-1) that have a prothrombotic effect. Another study has shown that leptin stimulates the expression of C-reactive protein (CRP) in coronary endothelial cells [[64]], creating a prothrombotic state in the coronary circulation [[65]].

2.4. Chemerin

Chemerin is a novel adipokine that is highly expressed in adipose tissue, liver, and cells of innate immunity [[66], [67]]. Recently, there has been a great interest in its potential role in the pathogenesis of cardiovascular disease in patients with MS. Several observational studies reported elevated levels of chemerin in obese patients [[68], [69]]. A recent study (2015) has investigated the role of chemerin in endothelial cell activation and early atherosclerotic changes in patients with newly diagnosed type II DM and showed that chemerin can increase the expression of endothelial adhesion molecules (ICAM-1 and E-selectin) that share in the early steps of forming an atherosclerotic plaque [[6]].

2.5. Omentin

Omentin is a recently discovered adipokine that is produced primarily by PVAT and vascular stromal cells [[63]]. Metabolically, omentin increases insulin-induced cellular signaling with promotion of insulin sensitivity within the adipose tissue. An inverse correlation exists between omentin levels and adiposity measures, including BMI and waist circumference [[70]]. Human studies reported diminished omentin levels in patients with severe coronary atherosclerosis, highlighting its role in preventing arterial calcification, which contributes to the development of atherosclerosis [[71][75]]. This antiatherogenic role is potentiated by its inhibitory effect on smooth muscle migration and proliferation [[76]]. Omentin has a NO-mediated vasodilator effect that can antagonize TNF-α mediated vasoconstriction [[63]]. Moreover, it inhibits expression of adhesion molecules such as E-selectin on endothelial cells, which play an important role in early stages of atherosclerosis [[77]].

2.6. Resistin

Human resistin is a 108 amino acid, cysteine-rich protein, encoded by a gene located on chromosome 19 [[78]]. It is a proinflammatory adipokine that is involved in the mechanism of IR, an action that is highly linked to the levels of other inflammatory adipocytokines such as leptin, TNF-α, and IL-6 [[79][82]]. Recent studies showed the presence of resistin-leptin cross-talk that regulates glucose metabolism and energy regulation [[83]].

Recent clinical studies indicated a positive correlation between high plasma levels of resistin and the severity of unstable angina (UA), atherosclerosis, and poor prognostic cases of coronary artery disease [[84], [85]]. Furthermore, patients with acute coronary syndrome (ACS) showed high levels of resistin with enhanced resistin gene expression within the adipose tissue, in comparison to cases of stable angina [[86]]. Experimental evidence supports the role of resistin in the pathogenesis of cardiovascular disease. Verma highlighted the potential role of resistin in endothelial dysfunction [[87]]. Other studies reported that resistin increased the release of endothelin, an effective vasoconstrictor in endothelial cells, and prothrombotic atherogenic factors such as plasminogen activator inhibitor-1 (PAI-1) and vWF that inhibit NO production [[87], [88]]. Moreover, resistin promotes smooth muscle cells proliferation and migration [[89], [90]] and increases the synthesis of prothrombotic tissue factor (TF) in human coronary cells [[91]].

2.7. Other Adipokines

Adipsin is a potential indicator of obesity in rodents. Although its role in energy homeostasis and systemic metabolism remains unknown, higher serum adipsin levels are found in diabetic and hypertensive patients [[92]]. Visfatin or PBEF (pre-B cell colony-enhancing factor) is involved in glucose uptake and metabolism because it stimulates insulin receptors [[93]]. It is also a prognostic factor of cardiovascular mortality because it plays a significant role in plaque destabilization of unstable carotid and coronary atherosclerosis [[94]].

Apelin (APE) is another adipokine that was known as the endogenous ligand of the orphan G-protein-coupled receptor. Elevated levels of apelin in obese mice reflect mild obesity-related inflammation, characterized by an increase in macrocytic count and high TNF-α levels. APE has a positive inotropic effect on the heart. Now, it is believed to be an angiotensin II homologue, performing beneficial effects on the aortic wall, causing its relaxation when used as a treatment [[94]].

Another proinflammatory adipocytokine is retinol binding protein-4 (RBP-4). Overexpression of RBP-4 triggers adipose tissue inflammation through the stimulation of both the innate and adaptive arms of the immune response [[95]]. RBP4 directly stimulates antigen-presenting cells, activating CD4+ T-helper cells, which trigger adipose tissue inflammation and, therefore, insulin resistance [[96]]. These data indicate that decreasing RBP4 levels, utilizing fenretinide or thiazolidinedione, constitutes a promising therapeutic strategy to improve insulin resistance; however, this mechanism has not been investigated in human trials [[22]]. The vascular effects of different adipokines are summarized in Figure 1.

3. Adipokines as Therapeutic Targets for Vascular Dysfunction

Based on the aforementioned vascular roles, several therapeutic strategies have been proposed and tested to improve vascular dysfunction in obese individuals and type II diabetics, including the following.

3.1. Increasing Adiponectin Activity

Several drugs with antidiabetic activity (glimepiride, peroxisome proliferator-activated receptor-alpha [PPARα] agonists: thiazolidinediones) [[97]], renin-angiotensin system (RAS) blocking effect such as losartan [[98][100]], and cholesterol/triglycerides lowering effect such as simvastatin or fenofibrate have been shown to increase adiponectin plasma levels in human and animal studies [[101]]. Fenofibrate therapy for two months markedly elevated plasma adiponectin levels and insulin sensitivity in patients with primary hypertriglyceridemia [[101], [102]]. Moreover, high plasma levels of adiponectin were noticed in humans receiving dietary fish oil [[103]]. Natural substances such as astragaloside II and isoastragaloside I (extracted from the medicinal herb Radix-Astragali) were shown to increase adiponectin plasma levels and reduce obesity-related insulin resistance [[104]].

Direct pharmacological administration of adiponectin has been shown to reduce glucose, lipid, and insulin concentrations and increase insulin receptor expression in obese diabetic mice on high fat diet [[105]]. A study by Kase et al. (2007) reported that treatment with globular adiponectin stimulated NF-κB of activated B cells and increased the expression of cohesive molecules and MCP-1 in endothelial cells by stimulation of the sphingosine kinase signaling pathway [[106]].

Lately, an orally active adiponectin receptor agonist “adipoRon” was proven to ameliorate insulin resistance and glucose intolerance in mice [[22], [107]]. An in vitro study has shown that osmotin, one of the pathogenesis related-5 (PR-5) family of plant defense proteins, is a potential adiponectin receptor agonist [[108]]. The three-dimensional structure of osmotin is similar to globular adiponectin; both are antiparallel β-strands arranged in the shape of a β-barrel. In addition, osmotin stimulates AMPK pathway via adiponectin receptors in mammalian C2C12 myocytes [[97]].

Repressed expression of the two adiponectin receptors (AdipoR1/AdipoR2) and hypoadiponectinemia have been shown in patients with type II DM [[109]] and in obese animals with insulin resistance and vascular dysfunction [[110]]. Therefore, enhancing AdipoR1/AdipoR2 expression or developing receptor agonists that can mimic adiponectin effects is a possible strategy to treat obesity-related vascular diseases [[97]]. Recent studies have shown that exercise, associated with a hypocaloric diet, increased AdipoR1 and AdipoR2 expression in skeletal muscle cells in older obese adults (>60 years of age) [[23], [111]]. In human macrophages, both PPARα and PPARγ agonists raised AdipoR2 expression only, while a synthetic LXR (liver X receptor) agonist activated the expression of both AdipoR1 and AdipoR2 [[112]].

3.2. Inhibiting A-FABP Activity

Based on the proinflammatory effects of A-FABP, pharmacological agents that inhibit its function may be a novel strategy for prevention of vascular dysfunction [[113]]. Animal studies have shown that pharmacologically induced reduction of A-FABP expression in apoE−/− mice on high fat diet markedly reduced aortic atherosclerotic lesions. Boord et al. reported that A-FABP null mice had a 67% higher survival rate, compared to control mice when both groups received high fat diet for one year [[114]].

Several A-FABP repressors such as arbazole-based repressors, benzylamino-6-(trifluoromethyl)pyrimidin-4(1H) repressors, and BMS309403 have been identified [[1], [115]]. BMS309403 interacts with the fatty acid binding pocket of A-FABP to antagonize binding of endogenous fatty acids [[116]]. Animal trials showed that treatment with BMS309403 reduces C-Jun NH2-terminal kinase (JNK) stimulation and production of proinflammatory cytokines [[113]]. An animal study by Furuhashi et al. showed that oral administration of BMS309403 reduced atherosclerotic lesions and enhanced insulin sensitivity and glucose tolerance in apoE−/− mice [[117]]. Until now, these effects of BMS309403 have not been tested in humans and further clinical trials are required before clinical development of this therapeutic agent.

3.3. The Relation between Adipokines and Anti-Inflammatory Drugs

The evidence of involvement of inflammatory pathways is confirmed by the protective activity of some anti-inflammatory drugs against obesity-related insulin resistance [[118]]. Aspirin can suppress not only JNK [[119], [120]], but other serine/threonine (Ser/Thr) protein kinases (mammalian target of rapamycin and protein kinase B/Akt) that induce IR by phosphorylation of insulin receptor substrate-1 (IRS-1) at serine residues [[120]]. Moreover, aspirin has been reported to inhibit the functionality of NF-κB or activator protein-1 (AP-1) which are associated with increased production of ROS [[121]]. Salicylates treatment has been proven to ameliorate acute insulin resistance in genetically obese rodents [[118], [122]]. Moreover, pretreatment of rats with salicylates protected against lipid-activated insulin resistance in skeletal muscles by suppressing IRS-1 tyrosine phosphorylation and accompanied phosphatidylinositide 3-kinase (PI-3K) stimulation [[123]]. Treatment with high doses of aspirin (7 g/day) or salicylates (3 g/day) ameliorated peripheral insulin sensitivity in type II DM patients [[124]]. Table 1 summarizes the vascular functions and diagnostic or therapeutic implications of different adipokines.

4. Future Research and Clinical Development of Adipokines

The pharmaceutical development of adipokines or adipokine inhibitor drugs for clinical use may face multiple obstacles, including lack of funding, high development cost, legislation, and licensure regulations [[125]]. Moreover, lack of human data on the safety and efficacy of many adipokines and deficient understanding of their mechanism of action can block further development of adipokine-based therapeutic strategies [[126]]. In the past 15 years, only leptin was developed into a drug following its discovery [[127], [128]] and the role of dipeptidyl peptidase-4 (DPP-4) as an adipokine was understood after it has been used for treatment of type II DM [[129], [130]]. Future research should focus on identifying the basic mechanism of action for several adipokines such as chemerin, resistin, and apelin. The drug development process takes 15 years on average: four to five years in the preclinical phase and then about eight years in clinical trials, and then the legislation and drug approval process start [[131]]. Innovative approaches should be followed to shorten this period, especially in the legislation step [[126]]. The potential role of adipokine-based therapies for vascular dysfunction, type II DM, and obesity, as well as neuroinflammatory diseases should be advocated and shared with the public and practicing physicians [[132], [133]].

5. Conclusion

Adipokines are bioactive molecules that have different effects on the vascular system. In obese and type II diabetics, IR causes dysfunction of the endocrine function of PVAT, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and increased production of ROS. Recent studies have shown that targeting plasma levels of adipokines or the expression of their receptors can increase insulin sensitivity, improve vascular function, and reduce the risk of cardiovascular morbidity and mortality. However, several human trials are required before further clinical development of these strategies. Further resources should be allocated to basic research to enhance our understanding of the vascular roles of adipokines and develop new therapeutic strategies to target these roles.

References

  1. A. XuY. WangK. S. I. LamP. M. VanhoutteVascular actions of adipokines: molecular mechanisms and therapeutic implicationsCardiovascular Pharmacology—Endothelial Control2010601stchapter 8Elsevier229255Advances in Pharmacology10.1016/B978-0-12-385061-4.00008-8
  2. J. D. J. Guerrero-GarcíaL. Carrera-QuintanarR. I. López-RoaMultiple sclerosis and obesity: possible roles of adipokinesMediators of Inflammation2016201624403623210.1155/2016/4036232
  3. Prospective Studies CollaborationBody-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet200937396691083109610.1016/S0140-6736(09)60318-42-s2.0-62849107573
  4. M. A. ViaJ. I. MechanickNutrition in type 2 diabetes and the metabolic syndromeMedical Clinics of North America201610061285130210.1016/j.mcna.2016.06.00927745595
  5. M. AguilarT. BhuketS. TorresB. LiuR. J. WongPrevalence of the metabolic syndrome in the United States, 2003-2012JAMA2015313191973197410.1001/jama.2015.42602-s2.0-8492950163625988468
  6. B. LuM. ZhaoW. JiangIndependent association of circulating level of chemerin with functional and early morphological vascular changes in newly diagnosed Type 2 diabetic patientsMedicine20159447e199010.1097/md.0000000000001990
  7. H. HaunerSecretory factors from human adipose tissue and their functional roleProceedings of the Nutrition Society200564216316910.1079/PNS20054282-s2.0-2044447145115960861
  8. M. W. RajalaP. E. SchererMinireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosisEndocrinology200314493765377310.1210/en.2003-05802-s2.0-004233025112933646
  9. H. TilgA. R. MoschenAdipocytokines: mediators linking adipose tissue, inflammation and immunityNature Reviews Immunology200661077278310.1038/nri19372-s2.0-33748992313
  10. B. WangI. S. WoodP. TrayhurnDysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytesPflügers Archiv—European Journal of Physiology2007455347949210.1007/s00424-007-0301-82-s2.0-3544893491317609976
  11. R. H. EckelS. M. GrundyP. Z. ZimmetThe metabolic syndromeLancet200536594681415142810.1016/S0140-6736(05)66378-72-s2.0-1714438082215836891
  12. S.-H. KimH.-S. ParkM. J. HongTongqiaohuoxue decoction ameliorates obesity-induced inflammation and the prothrombotic state by regulating adiponectin and plasminogen activator inhibitor-1Journal of Ethnopharmacology201619220120910.1016/j.jep.2016.07.0232-s2.0-8497957383227404230
  13. O. GualilloJ. R. González-JuanateyF. LagoThe emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectivesTrends in Cardiovascular Medicine200717827528310.1016/j.tcm.2007.09.0052-s2.0-3604900642418021938
  14. Y. CaoAdipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseasesNature Reviews Drug Discovery20109210711510.1038/nrd30552-s2.0-7584916554220118961
  15. S. RajshekerD. MankaA. L. BlomkalnsT. K. ChatterjeeL. L. StollN. L. WeintraubCrosstalk between perivascular adipose tissue and blood vesselsCurrent Opinion in Pharmacology201010219119610.1016/j.coph.2009.11.0052-s2.0-7794966981120060362
  16. T. K. ChatterjeeL. L. StollG. M. DenningProinflammatory phenotype of perivascular adipocytes: influence of high-fat feedingCirculation Research2009104454154910.1161/circresaha.108.1829982-s2.0-6194931855519122178
  17. Y.-J. GaoDual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunctionCurrent Pharmaceutical Design200713212185219210.2174/1381612077810396342-s2.0-3444752933417627551
  18. Y. DuR. LiW. B. LauAdiponectin at physiologically relevant concentrations enhances the vasorelaxative effect of acetylcholine via Cav-1/AdipoR-1 signalingPLoS ONE2016113e015224710.1371/journal.pone.01522472-s2.0-84962448886
  19. A. S. KellyJ. SteinbergerT. P. OlsonD. R. DengelIn the absence of weight loss, exercise training does not improve adipokines or oxidative stress in overweight childrenMetabolism: Clinical and Experimental20075671005100910.1016/j.metabol.2007.03.0092-s2.0-3425001708717570265
  20. V. KotsisS. StabouliS. PapakatsikaZ. RizosG. ParatiMechanisms of obesity-induced hypertensionHypertension Research201033538639310.1038/hr.2010.92-s2.0-7795196871620442753
  21. L. F. Van GaalI. L. MertensC. E. De BlockMechanisms linking obesity with cardiovascular diseaseNature2006444712187588010.1038/nature0548717167476
  22. V. Andrade-OliveiraN. O. S. CâmaraP. M. Moraes-VieiraAdipokines as drug targets in diabetes and underlying disturbancesJournal of Diabetes Research201520151168161210.1155/2015/6816122-s2.0-84928242180
  23. M. BlüherC. J. WilliamsN. KlötingGene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical trainingDiabetes Care200730123110311510.2337/dc07-12572-s2.0-3714905127517878241
  24. K. OhashiS. KiharaN. OuchiAdiponectin replenishment ameliorates obesity-related hypertensionHypertension20064761108111610.1161/01.hyp.0000222368.43759.a116651465
  25. M. E. TrujilloP. E. SchererAdiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndromeJournal of Internal Medicine2005257216717510.1111/j.1365-2796.2004.01426.x2-s2.0-1324428480615656875
  26. H. WakiT. YamauchiJ. KamonImpaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectinJournal of Biological Chemistry200327841403524036310.1074/jbc.M3003652002-s2.0-014192484912878598
  27. A. XuK. W. ChanR. L. C. HooTestosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytesThe Journal of Biological Chemistry200528018180731808010.1074/jbc.m4142312002-s2.0-2404447905515760892
  28. J. FruebisT.-S. TsaoS. JavorschiProteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in miceProceedings of the National Academy of Sciences of the United States of America20019842005201010.1073/pnas.0415917982-s2.0-003585276011172066
  29. T. YamauchiJ. KamonH. WakiThe fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesityNature Medicine20017894194610.1038/909842-s2.0-17944365228
  30. A. H. BergT. P. CombsX. DuM. BrownleeP. E. SchererThe adipocyte-secreted protein Acrp30 enhances hepatic insulin actionNature Medicine20017894795310.1038/909922-s2.0-0034881391
  31. A. XuY. WangH. KeshawL. Y. XuK. S. L. LamG. J. S. CooperThe fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in miceJournal of Clinical Investigation200311219110010.1172/JCI2003177972-s2.0-004130237712840063
  32. K. A. L. DarvallR. C. SamS. H. SilvermanA. W. BradburyD. J. AdamObesity and thrombosisEuropean Journal of Vascular and Endovascular Surgery200733222323310.1016/j.ejvs.2006.10.0062-s2.0-3384616576217185009
  33. M. A. LynchThe multifaceted profile of activated microgliaMolecular Neurobiology200940213915610.1007/s12035-009-8077-92-s2.0-7304911076719629762
  34. R. OuedraogoX. WuS.-Q. XuAdiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathwayDiabetes20065561840184610.2337/db05-11742-s2.0-3374831058616731851
  35. G. P. FadiniS. SartoreC. AgostiniA. AvogaroSignificance of endothelial progenitor cells in subjects with diabetesDiabetes Care20073051305131310.2337/dc06-23052-s2.0-3424763509617277037
  36. R. ShibataC. SkurkN. OuchiAdiponectin promotes endothelial progenitor cell number and functionFEBS Letters2008582111607161210.1016/j.febslet.2008.04.0062-s2.0-4274908883018423403
  37. H. MotoshimaX. WuK. MahadevB. J. GoldsteinAdiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDLBiochemical and Biophysical Research Communications2004315226427110.1016/j.bbrc.2004.01.0492-s2.0-084233223114766203
  38. W. ZhuK. ChengP. VanhoutteK. LamA. XuVascular effects of adiponectin: molecular mechanisms and potential therapeutic interventionClinical Science2008114536137410.1042/CS2007034718230060
  39. N. OuchiS. KiharaY. AritaY. OkamotoAdiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathwayCirculation2000102111296130110.1161/01.CIR.102.11.129610982546
  40. C. KobashiM. UrakazeM. KishidaAdiponectin inhibits endothelial synthesis of interleukin-8Circulation Research200597121245125210.1161/01.RES.0000194328.57164.362-s2.0-3364468306516269654
  41. S. B. HongJ. J. LeeS. H. KimThe effects of adiponectin and inflammatory cytokines on diabetic vascular complications in obese and non-obese patients with type 2 diabetes mellitusDiabetes Research and Clinical Practice2016111586510.1016/j.diabres.2015.10.0172-s2.0-8495755728426589367
  42. B. WangJ. R. JenkinsP. TrayhurnExpression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-αAmerican Journal of Physiology—Endocrinology and Metabolism20052884E731E74010.1152/ajpendo.00475.20042-s2.0-1544436703615562246
  43. N. KubotaY. TerauchiT. YamauchiDisruption of adiponectin causes insulin resistance and neointimal formationJournal of Biological Chemistry200227729258632586610.1074/jbc.C2002512002-s2.0-003713552312032136
  44. K.-W. LiangW. H.-H. SheuW.-L. LeeDecreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectorisInternational Journal of Cardiology20081291768010.1016/j.ijcard.2007.05.0272-s2.0-4934910455517651832
  45. R. ShibataK. SatoD. R. PimentelAdiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanismsNature Medicine200511101096110310.1038/nm12952-s2.0-27144457438
  46. J. E. HallThe kidney, hypertension, and obesityHypertension200341362563310.1161/01.hyp.0000052314.95497.7812623970
  47. D. H. KimC. KimE. L. DingM. K. TownsendL. A. LipsitzAdiponectin levels and the risk of hypertension: a systematic review and meta-analysisHypertension2013621273210.1161/hypertensionaha.113.0145323716587
  48. R. L. C. HooD. C. Y. YeungK. S. L. LamA. XuInflammatory biomarkers associated with obesity and insulin resistance: a focus on lipocalin-2 and adipocyte fatty acid-binding proteinExpert Review of Endocrinology and Metabolism200831294110.1586/17446651.3.1.292-s2.0-37549058420
  49. A. XuAdipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndromeClinical Chemistry200652340541310.1373/clinchem.2005.06246316423904
  50. E. J. RheeW. Y. LeeC. Y. ParkThe association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adultsEuropean Journal of Endocrinology2009160216517210.1530/EJE-08-06652-s2.0-6144922465519001529
  51. A. XuA. W. K. TsoB. M. Y. CheungCirculating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective studyCirculation2007115121537154310.1161/circulationaha.106.6475032-s2.0-3424747213817389279
  52. X. HuiH. LiZ. ZhouAdipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH 2-terminal kinases and activator protein-1Journal of Biological Chemistry201028514102731028010.1074/jbc.M109.0979072-s2.0-7795123267420145251
  53. S. SöderbergB. AhrénJ.-H. JanssonLeptin is associated with increased risk of myocardial infarctionJournal of Internal Medicine1999246440941810.1046/j.1365-2796.1999.00571.x2-s2.0-003286203710583712
  54. S. SöderbergB. AhrénB. StegmayrLeptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohortStroke199930232833710.1161/01.STR.30.2.3282-s2.0-03449594529933268
  55. A. M. WallaceA. D. McMahonC. J. PackardPlasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS)Circulation2001104253052305610.1161/hc5001.1010612-s2.0-003590999711748099
  56. R. WolkP. BergerR. J. LennonE. S. BrilakisB. D. JohnsonV. K. SomersPlasma leptin and prognosis in patients with established coronary atherosclerosisJournal of the American College of Cardiology20044491819182410.1016/j.jacc.2004.07.0502-s2.0-704422280815519013
  57. F. MolicaS. MorelB. R. KwakF. Rohner-JeanrenaudS. SteffensAdipokines at the crossroad between obesity and cardiovascular diseaseThrombosis and Haemostasis2016113355356610.1160/TH14-06-05132-s2.0-84924145646
  58. G. LemboC. VecchioneL. FrattaLeptin induces direct vasodilation through distinct endothelial mechanismsDiabetes200049229329710.2337/diabetes.49.2.2932-s2.0-003397846710868946
  59. J. E. HallA. A. Da SilvaJ. M. Do CarmoObesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortinsJournal of Biological Chemistry201028523172711727610.1074/jbc.r110.1131752-s2.0-7795289330120348094
  60. M. OzataI. C. OzdemirJ. LicinioHuman leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defectsJournal of Clinical Endocrinology and Metabolism199984103686369510.1210/jcem.84.10.59992-s2.0-003330457610523015
  61. S. KonstantinidesK. SchäferS. KoschnickD. J. LoskutoffLeptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesityThe Journal of Clinical Investigation2001108101533154010.1172/jci2001131432-s2.0-003517908711714745
  62. P. F. BodaryR. J. WestrickK. J. WickenheiserY. ShenD. T. EitzmanEffect of leptin on arterial thrombosis following vascular injury in miceJournal of the American Medical Association2002287131706170910.1001/jama.287.13.17062-s2.0-003701248311926895
  63. F. MarescaV. Di PalmaM. BevilacquaAdipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular diseaseAngiology201466182410.1177/00033197135204632-s2.0-8492717267824535638
  64. S. De RosaP. CirilloM. PacileoV. Di PalmaA. PagliaM. ChiarielloLeptin stimulated c-reactive protein production by human coronary artery endothelial cellsJournal of Vascular Research200946660961710.1159/0002262292-s2.0-6764944596919571581
  65. P. CirilloP. GolinoP. CalabròC-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferationCardiovascular Research2005681475510.1016/j.cardiores.2005.05.0102-s2.0-2434449041716023093
  66. K. BozaogluK. BoltonJ. McMillanChemerin is a novel adipokine associated with obesity and metabolic syndromeEndocrinology2007148104687469410.1210/en.2007-01752-s2.0-3474881738617640997
  67. M. C. ErnstC. J. SinalChemerin: at the crossroads of inflammation and obesityTrends in Endocrinology and Metabolism2010211166066710.1016/j.tem.2010.08.0012-s2.0-7804931411820817486
  68. A. A. Verrijn StuartH. S. SchipperI. TasdelenAltered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetesJournal of Clinical Endocrinology and Metabolism201297246347210.1210/jc.2011-18582-s2.0-8485681047422112811
  69. H. O. El-MesallamyM. O. El-DeranyN. M. HamdySerum omentin-1 and chemerin levels are interrelated in patients with Type2 diabetes mellitus with or without ischaemic heart diseaseDiabetic Medicine201128101194120010.1111/j.1464-5491.2011.03353.x2-s2.0-8005303616321668495
  70. C. M. De Souza BatistaR.-Z. YangM.-J. LeeOmentin plasma levels and gene expression are decreased in obesityDiabetes20075661655166110.2337/db06-15062-s2.0-3424967452017329619
  71. R. ShibataN. OuchiR. KikuchiCirculating omentin is associated with coronary artery disease in menAtherosclerosis2011219281181410.1016/j.atherosclerosis.2011.08.0172-s2.0-8295518445921925659
  72. X. ZhongH.-Y. ZhangH. TanAssociation of serum omentin-1 levels with coronary artery diseaseActa Pharmacologica Sinica201132787387810.1038/aps.2011.262-s2.0-7996005823221602837
  73. B. LiL. ZhangX. YangX. LiuY. RenSerum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndromeClinical and Investigative Medicine. Médecine Clinique et Experimentale2010336E398E40421134342
  74. X.-Y. DuanP.-L. XieY.-L. MaS.-Y. TangOmentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathwayAmino Acids20114151223123110.1007/s00726-010-0800-32-s2.0-8485521017321082206
  75. R. LiuX. WangP. BuOmentin-1 is associated with carotid atherosclerosis in patients with metabolic syndromeDiabetes Research and Clinical Practice2011931212510.1016/j.diabres.2011.03.0012-s2.0-7996055940821497934
  76. S. GreulichW. J. Y. ChenB. MaxheraCardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studiesPLoS ONE201383e5969710.1371/journal.pone.0059697
  77. H. YamawakiN. TsubakiM. MukohdaM. OkadaY. HaraOmentin, a novel adipokine, induces vasodilation in rat isolated blood vesselsBiochemical and Biophysical Research Communications2010393466867210.1016/j.bbrc.2010.02.0532-s2.0-7794948464420170632
  78. C. M. SteppanE. J. BrownC. M. WrightA family of tissue-specific resistin-like moleculesProceedings of the National Academy of Sciences of the United States of America200198250250610.1073/pnas.98.2.5022-s2.0-003589520111209052
  79. S. YaturuR. P. DaberryJ. RainsS. JainResistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetesCytokine2006343-421922310.1016/j.cyto.2006.05.0052-s2.0-3374580625116822679
  80. M. P. ReillyM. LehrkeM. L. WolfeA. RohatgiM. A. LazarD. J. RaderResistin is an inflammatory marker of atherosclerosis in humansCirculation2005111793293910.1161/01.CIR.0000155620.10387.432-s2.0-1404425721115710760
  81. M. S. BurnettC. W. LeeT. D. KinnairdThe potential role of resistin in atherogenesisAtherosclerosis2005182224124810.1016/j.atherosclerosis.2005.02.0142-s2.0-2464447927616159596
  82. M. FilkováH. HulejováK. KuncováResistin in idiopathic inflammatory myopathiesArthritis Research and Therapy2012143, article no. R11110.1186/ar38362-s2.0-84860818276
  83. Y. QiZ. NieY.-S. LeeLoss of resistin improves glucose homeostasis in leptin deficiencyDiabetes200655113083309010.2337/db05-06152-s2.0-3384552228717065346
  84. E. LubosC. M. MessowR. SchnabelResistin, acute coronary syndrome and prognosis results from the AtheroGene studyAtherosclerosis2007193112112810.1016/j.atherosclerosis.2006.05.0392-s2.0-3424910493816814296
  85. G. D. NorataM. OngariK. GarlaschelliS. RaselliL. GrigoreA. L. CatapanoPlasma resistin levels correlate with determinants of the metabolic syndromeEuropean Journal of Endocrinology2007156227928410.1530/eje.1.023382-s2.0-3394772521617287419
  86. S. LangheimL. DreasL. VeschiniIncreased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndromeAmerican Journal of Physiology—Heart and Circulatory Physiology20102983H746H75310.1152/ajpheart.00617.20092-s2.0-7774927959520061546
  87. S. VermaResistin promotes endothelial cell activation: further evidence of adipokine-endothelial interactionCirculation2003108673674010.1161/01.cir.0000084503.91330.4912874180
  88. Y. LiY. WangQ. LiEffect of resistin on vascular endothelium secretion dysfunction in ratsEndothelium: Journal of Endothelial Cell Research2007144-520721410.1080/106233207016172252-s2.0-3514886620817922337
  89. P. CalabroI. SamudioJ. T. WillersonE. T. H. YehResistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathwaysCirculation2004110213335334010.1161/01.CIR.0000147825.97879.E72-s2.0-934425282015545519
  90. H. S. JungK.-H. ParkY. M. ChoResistin is secreted from macrophages in atheromas and promotes atherosclerosisCardiovascular Research2006691768510.1016/j.cardiores.2005.09.0152-s2.0-2914443282216271710
  91. P. CalabròP. CirilloG. LimongelliTissue factor is induced by resistin in human coronary artery endothelial cells by the NF-κB-dependent pathwayJournal of Vascular Research2010481596610.1159/0003187752-s2.0-7795441834420628259
  92. A. HietaharjuH. KuusistoR. NieminenK. VuolteenahoI. ElovaaraE. MoilanenElevated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple sclerosis: A Finnish Co-Twin StudyEuropean Journal of Neurology201017233233410.1111/j.1468-1331.2009.02701.x2-s2.0-7454921876319538214
  93. Ł. KraszulaA. JasińskaM.-O. EusebioP. KunaA. GłabińskiM. PietruczukEvaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosisNeurologia i Neurochirurgia Polska2012461222810.5114/ninp.2012.272112-s2.0-8485883951222426759
  94. E. KantorováĽ. JesenskáD. ČiernyThe intricate network of adipokines and strokeInternational Journal of Endocrinology20152015896769810.1155/2015/967698
  95. J. NorseenT. HosookaA. HammarstedtRetinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanismMolecular and Cellular Biology201232102010201910.1128/MCB.06193-112-s2.0-8486140364122431523
  96. P. M. Moraes-VieiraM. M. YoreP. M. DwyerI. SyedP. AryalB. B. KahnRBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistanceCell Metabolism201419351252610.1016/j.cmet.2014.01.0182-s2.0-8489574155224606904
  97. W. ZhuK. K. Y. ChengP. M. VanhoutteK. S. L. LamA. XuVascular effects of adiponectin: molecular mechanisms and potential therapeutic interventionClinical Science2008114536137410.1042/cs200703472-s2.0-3954909471718230060
  98. R. ClasenM. SchuppA. Foryst-LudwigPPARγ-activating angiotensin type-1 receptor blockers induce adiponectinHypertension200546113714310.1161/01.HYP.0000168046.19884.6a2-s2.0-2174445298315939809
  99. M. FuruhashiN. UraK. HigashiuraBlockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertensionHypertension2003421768110.1161/01.HYP.0000078490.59735.6E2-s2.0-003881855212796280
  100. K. K. KwangM. J. QuonH. H. SeungAdditive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patientsCirculation2004110243687369210.1161/01.CIR.0000143085.86697.132-s2.0-2084445621515569835
  101. U. B. PajvaniM. HawkinsT. P. CombsComplex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivityThe Journal of Biological Chemistry200427913121521216210.1074/jbc.m3111132002-s2.0-1114435563714699128
  102. K. K. KohS. H. HanM. J. QuonJ. Y. AhnE. K. ShinBeneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemiaDiabetes Care20052861419142410.2337/diacare.28.6.14192-s2.0-1994437983515920062
  103. W. ZhuK. K. Y. ChengP. M. VanhoutteK. S. L. LamA. XuVascular effects of adiponectin: molecular mechanisms and potential therapeutic interventionClinical Science20081145-636137410.1042/cs200703472-s2.0-3954909471718230060
  104. A. XuH. WangR. L. C. HooSelective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese miceEndocrinology2009150262563310.1210/en.2008-09992-s2.0-5964911707218927219
  105. H. MaF. CuiJ.-J. DongTherapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver diseaseWorld Journal of Gastroenterology20142040149501495710.3748/wjg.v20.i40.149502-s2.0-8491063915525356056
  106. H. KaseY. HattoriT. JojimaGlobular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cellsLife Sciences2007811193994310.1016/j.lfs.2007.08.0022-s2.0-3454847923217822721
  107. M. Okada-IwabuT. YamauchiM. IwabuA small-molecule AdipoR agonist for type 2 diabetes and short life in obesityNature2013503747749349910.1038/nature126562-s2.0-8488863995224172895
  108. M. L. NarasimhanM. A. CocaJ. JinOsmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptorMolecular Cell20051717118010.1016/j.molcel.2004.11.05015664187
  109. C. DebardM. LavilleV. BerbeExpression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patientsDiabetologia200447591792510.1007/s00125-004-1394-72-s2.0-294262268015127202
  110. A. E. CivitareseC. P. JenkinsonD. RichardsonAdiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetesDiabetologia200447581682010.1007/s00125-004-1359-x2-s2.0-294259475515105989
  111. V. B. O'LearyA. E. JorettC. M. MarchettiEnhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adultsAmerican Journal of Physiology—Endocrinology and Metabolism20072931E421E42710.1152/ajpendo.00123.20072-s2.0-3454711685117488807
  112. G. ChinettiC. ZawadskiJ. C. FruchartB. StaelsExpression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXRBiochemical and Biophysical Research Communications2004314115115810.1016/j.bbrc.2003.12.0582-s2.0-034798652014715259
  113. E. ErbayV. R. BabaevJ. R. MayersReducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosisNature Medicine20091513831391
  114. J. B. BoordK. MaedaL. MakowskiAdipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology200222101686169110.1161/01.ATV.0000033090.81345.E62-s2.0-0036790535
  115. M. FuruhashiG. S. HotamisligilFatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNature Reviews Drug Discovery20087648950310.1038/nrd25892-s2.0-4444911892118511927
  116. R. SulskyD. R. MagninY. HuangPotent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)Bioorganic and Medicinal Chemistry Letters200717123511351510.1016/j.bmcl.2006.12.0442-s2.0-3424972718817502136
  117. M. FuruhashiG. TuncmanC. Z. GörgünTreatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2Nature2007447714795996510.1038/nature058442-s2.0-3425090418617554340
  118. W. L. HenryPerspectives in diabetesJournal of the National Medical Association1962544764782-s2.0-7304917970013906557
  119. M.-J. YinY. YamamotoR. B. GaynorThe anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-βNature19983966706778010.1038/239482-s2.0-00324878579817203
  120. Z. GaoA. ZuberiM. J. QuonZ. DongJ. YeAspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinasesThe Journal of Biological Chemistry200327827249442495010.1074/jbc.m3004232002-s2.0-004259126112714600
  121. X. ShiM. DingZ. DongAntioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-κB activation, and TNF-α productionMolecular and Cellular Biochemistry19991991-29310210.1023/a:10069346123682-s2.0-003284846710544957
  122. M. YuanN. KonstantopoulosJ. LeeReversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IkkβScience200129355351673167710.1126/science.10616202-s2.0-003597977511533494
  123. J. K. KimY. KimJ. J. FillmorePrevention of fat-induced insulin resistance by salicylateJournal of Clinical Investigation2001108343744610.1172/JCI20011155911489937
  124. R. S. HundalK. F. PetersenA. B. MayersonMechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetesThe Journal of Clinical Investigation2002109101321132610.1172/jci2002149552-s2.0-003609985712021247
  125. R. J. RodgersM. H. TschöpJ. P. H. WildingAnti-obesity drugs: past, present and futureDMM Disease Models and Mechanisms20125562162610.1242/dmm.0096212-s2.0-8486550429022915024
  126. C. M. KusminskiP. E. SchererThe road from discovery to clinic: adiponectin as a biomarker of metabolic statusClinical Pharmacology & Therapeutics200986659259510.1038/clpt.2009.1552-s2.0-7045013417719915603
  127. E. A. OralV. SimhaE. RuizLeptin-replacement therapy for lipodystrophyNew England Journal of Medicine2002346857057810.1056/NEJMoa0124372-s2.0-003714892811856796
  128. I. S. FarooqiS. A. JebbG. LangmackEffects of recombinant leptin therapy in a child with congenital leptin deficiencyThe New England Journal of Medicine19993411287988410.1056/nejm1999091634112042-s2.0-003357599310486419
  129. D. LamersS. FamullaN. WronkowitzDipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndromeDiabetes20116071917192510.2337/db10-17072-s2.0-8005209659521593202
  130. H. SellM. BlüherN. KlötingAdipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitroDiabetes Care201336124083409010.2337/dc13-04962-s2.0-8489188811224130353
  131. J. A. DiMasiNew drug development in the United States from 1963 to 1999Clinical Pharmacology & Therapeutics200169528629610.1067/mcp.2001.1151322-s2.0-003533655711371996
  132. M. BlüherA. RudichN. KlötingTwo patterns of adipokine and other biomarker dynamics in a long-term weight loss interventionDiabetes Care201235234234910.2337/dc11-12672-s2.0-8485904160322190676
  133. A. I. AbushoukN. M. DucCuring neurophobia in medical schools: evidence-based strategiesMedical Education Online2016213247610.3402/meo.v21.32476
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5327767/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as type 2 diabetes mellitus.